Pronacera Therapeutics

What Pronacera Therapeutics does

Pronacera Therapeutics S.L. is a privately held Spanish biotechnology company founded in 2015 and headquartered in Sevilla (with a registered address in Olivares, Sevilla), focused on molecular diagnostics for reproductive health, fibromyalgia, and gut microbiome-related conditions. The company develops and markets a portfolio of B2B diagnostic tests, including the MiFERT&i endometrial transcriptomics/immunology/microbiology panel for window-of-implantation assessment, the Emi seminal microbiome test, Karyotype and Vaginal Microbiome tests, the Heres carrier screening suite with three panel sizes (30 to 1,200+ genes), the TromboCare thrombophilia genetic test (99% reported precision), the Eba mitochondrial/microbiota suite with three complexity tiers, and the Fibrokit biomarker assay for fibromyalgia. Underlying methods combine transcriptomics, immunology, microbiology (16S/18S/ITS sequencing), and multi-gene genetic analysis, supported by published peer-reviewed research and an in-house laboratory in Sevilla.

The company operates a B2B distribution model, selling diagnostic kits and services through partnered fertility clinics, embryologists, and medical professionals across Spain and Latin America (Peru, Mexico, Chile, Colombia, Argentina), with a regional subsidiary in Argentina and a dedicated professional results portal (Zendolims). It supplements this with direct-to-consumer personalized nutrition services for individuals and corporate wellness offerings. Revenue is generated primarily through one-time per-test pricing to clinical partners; public pricing is largely undisclosed. The team is small (11–50 employees per LinkedIn), the company is privately held with no disclosed funding rounds or revenue figures, and its outbound marketing relies on LinkedIn, Facebook, peer-reviewed publications, and conference participation (e.g., ESHRE 2026) to reach clinics and patient communities.

Name

Pronacera Therapeutics

Legal name

PRONACERA THERAPEUTICS, S.L.

Website

https://pronacera.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Pronacera Therapeutics is a Sevilla-based molecular diagnostics company offering B2B genetic and microbiome tests for fertility clinics, plus a small direct nutrition service, serving reproductive health specialists and patients across Spain and Latin America.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

Keywords

• Molecular diagnostic tests
• Reproductive genetic testing
• Gut microbiome analysis
• Carrier genetic screening
• Fibromyalgia diagnostics

Headquarters

HQ city

Sevilla

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Genetic Diagnostic Tests (B2B): Pronacera sells a range of genetic diagnostic tests to fertility clinics and medical professionals, who then deliver these services to patients. Revenue is generated through product sales to B2B partners.
2. Nutrition Services: Personalized nutrition consulting services offered to individuals, including meal plans and ongoing nutritional follow-up consultations. Can include corporate nutrition services for companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Pronacera Therapeutics develops and sells advanced molecular diagnostic tests focused on reproductive genetics, gut microbiome investigation, and fibromyalgia biomarker analysis. Its portfolio includes the Karyotype Test, MiFERT&i endometrial analysis, Emi seminal microbiome test, Heres carrier screening panels, TromboCare thrombophilia test, Eba mitochondrial/microbiota tests, and Fibrokit, which are delivered primarily through partnered fertility clinics and medical professionals. The company also offers a personalised nutrition service grounded in biomarker and genetic test interpretation.

Product overview

Pronacera Therapeutics is a biotechnology company offering advanced molecular diagnostic tools organized into three main product categories: Reproductive Health tests (Karyotype Test, MiFERT&i Test, Vaginal Microbiome Test, Emi Test, Heres Test with three sub-panels - Initia, Seq, Liber, and TromboCare Test), General Health tests (Eba Test with three variants - Eba, Eba Plus, and Eba Active, and Nutrition Service), and Fibromyalgia testing (Fibrokit). The company combines reproductive genomics, gut microbiome analysis, and functional endometrial molecular biology to provide faster and more precise diagnostics in areas of assisted reproduction, nutrition, fibromyalgia, and general health.

Differentiator

Problem solved

Functional benefit

Brands

• MiFERT&i Test: Comprehensive endometrial analysis combining transcriptomics, immunology, and microbiology to identify the window of implantation for assisted reproduction.
• Fibrokit
• Eba Test
• TromboCare
• Heres Carrier Screening
• Emi Test
• Karyotype Test

Products and services

• Karyotype Test Essential genetic analysis in fertility studies to detect abnormalities in chromosome structure or number; used to prevent recurrent miscarriages, congenital malformations, and identify genetic causes of infertility.
• MiFERT&i Test
• Vaginal Microbiome Test
• Emi Test
• Heres Test
• TromboCare Test
• Fibrokit
• Eba Test
• Nutrition Service

Quantifiable outcome

• 99% high-precision genetic technology for TromboCare thrombophilia test
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Regenera EspañaminorStrategic or Co-development Partner · 30 June 2026Special collaboration with Regenera España for the Buenos Aires workshop, with David Vargas and Carlos Pérez Ramírez sharing experience in integrative health approaches alongside Pronacera's diagnostic expertise.
• SAEC – Sociedad Argentina de Embriología ClínicaminorStrategic or Co-development Partner · 27 June 2026Host venue partner for the Pronacera Argentina workshop on integrative health. SAEC (Argentine Society of Clinical Embryology) provided the location for the workshop on June 26, 2026, in Buenos Aires.
• MetabolomcoreStrategic or Co-development Partner · 26 June 2026Pronacera partnered with Metabolom to host an integrative workshop in Buenos Aires focused on biochemistry, microbiota, and clinical practice. The workshop was aimed at healthcare professionals interested in the relationship between microbiota, metabolism, immune system, and nervous system, combining scientific evidence with clinical application.
• Healthcare Institutions Across Spain and Latin AmericacoreChannel Partner/ Reseller/ DistributorPronacera collaborates with institutions and companies from Spain, Peru, Mexico, Chile, Colombia, Argentina, and other Latin American countries to advance precision medicine development. These are primarily B2B channel partnerships where clinics and medical professionals distribute Pronacera's diagnostic products.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Myriad Genetics: Established diagnostics company with hereditary cancer, pharmacogenomic, and reproductive health (Prequel, Foresight) carrier screening tests; broader portfolio and payor relationships position it as a competing incumbent for clinic contracts.
• SYNLAB: Large European clinical diagnostics network providing medical and specialty laboratory testing including reproductive and genetic diagnostics; competes broadly with Pronacera's medical laboratory services across European markets.
• Invitae: Broad genetic testing platform spanning reproductive, hereditary cancer, and rare disease; competes directly with Pronacera's Heres carrier screening and karyotype offerings, and has wider payor coverage and clinical utility data.
• BGI Genomics: Global genomics company with NIPT, carrier screening, and reproductive health offerings at very high scale and low cost; poses a long-term price-competition risk for Pronacera's carrier screening SKUs.
• Sema4 (GeneDx): Genomic diagnostics company (GeneDx following Sema4 spin) offering reproductive and rare-disease genetic testing; overlaps with Pronacera's Heres carrier screening and karyotype, with stronger US payor footprint.
• Eurofins Genoma: European-based molecular diagnostics lab within the Eurofins network offering reproductive genetics, NIPT, and carrier screening; the closest European incumbent comparable to Pronacera on geography and B2B clinic channel.

Direct peers

• Natera: US-listed reproductive and oncology genetic testing company offering carrier screening (Vistara), PGT, and hereditary cancer panels B2B through clinics and physicians; comparable in test menu and channel model, though at much larger scale.
• Igenomix (Vitrolife): Global reproductive genetics lab offering PGT-A, carrier screening, endometrial receptivity (ERA), and microbiome testing sold B2B to fertility clinics — the most direct analog to Pronacera's reproductive workflow, including the comparable endometrial transcriptomics approach.

Emerging players

• Genomic Prediction: Specialized reproductive genetics lab focused on PGT and embryo screening using NGS; smaller and more niche than Natera/Invitae but competes for the same fertility-clinic channel in advanced reproductive testing.
• MicroGen Diagnostics / Gut Microbiome Testing Labs: Emerging specialty labs in microbiome and gut health diagnostics; partial overlap with Pronacera's Eba and Emi microbiome offerings, illustrating both the contested clinical validity and the crowding of this category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/pronacera.therapeutics
• LinkedInlinkedin.com/company/pronacera
• Xx.com/Pronacera

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pronacera Therapeutics